Scopus BioPharma Competitors

AbCellera Biologics (NASDAQ:ABCL) and Scopus BioPharma (NASDAQ:SCPS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares AbCellera Biologics and Scopus BioPharma's top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares AbCellera Biologics and Scopus BioPharma's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and target prices for AbCellera Biologics and Scopus BioPharma, as provided by MarketBeat.

AbCellera Biologics presently has a consensus price target of $52.80, indicating a potential upside of 86.90%. Scopus BioPharma has a consensus price target of $20.00, indicating a potential upside of 155.75%. Given Scopus BioPharma's higher possible upside, analysts clearly believe Scopus BioPharma is more favorable than AbCellera Biologics.

Summary

AbCellera Biologics beats Scopus BioPharma on 2 of the 3 factors compared between the two stocks.

Sana Biotechnology (NASDAQ:SANA) and Scopus BioPharma (NASDAQ:SCPS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Sana Biotechnology and Scopus BioPharma's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Sana Biotechnology and Scopus BioPharma, as provided by MarketBeat.

Sana Biotechnology presently has a consensus price target of $40.00, indicating a potential upside of 59.74%. Scopus BioPharma has a consensus price target of $20.00, indicating a potential upside of 155.75%. Given Scopus BioPharma's higher possible upside, analysts clearly believe Scopus BioPharma is more favorable than Sana Biotechnology.

Earnings & Valuation

This table compares Sana Biotechnology and Scopus BioPharma's top-line revenue, earnings per share (EPS) and valuation.

Summary

Sana Biotechnology beats Scopus BioPharma on 2 of the 3 factors compared between the two stocks.

Scopus BioPharma (NASDAQ:SCPS) and Abcam (NASDAQ:ABCM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Valuation & Earnings

This table compares Scopus BioPharma and Abcam's top-line revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a breakdown of current ratings and price targets for Scopus BioPharma and Abcam, as provided by MarketBeat.com.

Scopus BioPharma currently has a consensus target price of $20.00, indicating a potential upside of 155.75%. Abcam has a consensus target price of $22.00, indicating a potential upside of 12.47%. Given Scopus BioPharma's higher possible upside, research analysts clearly believe Scopus BioPharma is more favorable than Abcam.

Profitability

This table compares Scopus BioPharma and Abcam's net margins, return on equity and return on assets.

Summary

Abcam beats Scopus BioPharma on 2 of the 3 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Scopus BioPharma (NASDAQ:SCPS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.

Profitability

This table compares Seer and Scopus BioPharma's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Seer and Scopus BioPharma's gross revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Seer and Scopus BioPharma, as reported by MarketBeat.

Seer currently has a consensus target price of $68.00, indicating a potential upside of 26.25%. Scopus BioPharma has a consensus target price of $20.00, indicating a potential upside of 155.75%. Given Scopus BioPharma's higher probable upside, analysts plainly believe Scopus BioPharma is more favorable than Seer.

Summary

Seer beats Scopus BioPharma on 2 of the 3 factors compared between the two stocks.

Nuvation Bio (NYSE:NUVB) and Scopus BioPharma (NASDAQ:SCPS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.

Profitability

This table compares Nuvation Bio and Scopus BioPharma's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Nuvation Bio and Scopus BioPharma's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of recent ratings for Nuvation Bio and Scopus BioPharma, as reported by MarketBeat.com.

Nuvation Bio currently has a consensus price target of $17.40, indicating a potential upside of 74.52%. Scopus BioPharma has a consensus price target of $20.00, indicating a potential upside of 155.75%. Given Scopus BioPharma's higher probable upside, analysts clearly believe Scopus BioPharma is more favorable than Nuvation Bio.

Summary

Nuvation Bio beats Scopus BioPharma on 2 of the 3 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and Scopus BioPharma (NASDAQ:SCPS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Profitability

This table compares ImmunityBio and Scopus BioPharma's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for ImmunityBio and Scopus BioPharma, as reported by MarketBeat.

ImmunityBio presently has a consensus price target of $25.00, suggesting a potential upside of 38.35%. Scopus BioPharma has a consensus price target of $20.00, suggesting a potential upside of 155.75%. Given Scopus BioPharma's higher probable upside, analysts clearly believe Scopus BioPharma is more favorable than ImmunityBio.

Valuation and Earnings

This table compares ImmunityBio and Scopus BioPharma's gross revenue, earnings per share and valuation.

Summary

ImmunityBio beats Scopus BioPharma on 2 of the 3 factors compared between the two stocks.